Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Eligibility criteria
Qualifiers
Patients ≥ 18 years
Newly diagnosed lymphoma
Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
Eastern Cooperative Oncology Group (ECOG) performance status 0-3
Disqualifiers
Prior anthracycline treatment
Previous malignancy requiring any chemotherapy or radiotherapy
Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
Trial design
Treatments tested in this trial
- Sotagliflozin
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1Icahn School of Medicine at Mount Sinai10029, New YorkNew York, United States
Sponsors and collaborators
Icahn School of Medicine at Mount Sinai
Lead sponsor
American Heart Association
Collaborator
Source ClinicalTrials.gov